ImmunoGen

$7.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.56%) As of 2:08 PM UTC today

Why Robinhood?

You can buy or sell ImmunoGen and other stocks, options, and ETFs commission-free!

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151.

CEO
Mark J. Enyedy
Employees
79
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
1.49B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.04M
High Today
$7.30
Low Today
$7.15
Open Price
$7.15
Volume
208.88K
52 Week High
$10.88
52 Week Low
$3.34

IMGN Earnings

-$0.18
-$0.07
$0.05
$0.16
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Apr 30, Pre-Market

You May Also Like

CPTK+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure